Prevention of Hepatocellular Carcinoma (HCC). White Paper of the Texas Collaborative Center for Hepatocellular Cancer (TeCH) Multi-stakeholder Conference

Abstract

Texas has the highest age-adjusted incidence rate of hepatocellular carcinoma (HCC) in the United States.1 The Cancer Prevention and Research Institute of Texas (CPRIT) has funded the Texas Collaborative Center for Hepatocellular Cancer (TeCH) to facilitate HCC research, education and advocacy activities with the overall goal of reducing HCC mortality in Texas through coordination, collaboration and advocacy.2 METHODS: On September 17, 2022, TeCH co-sponsored a multi-stakeholder conference on HCC with the Baker Institute Center for Health and Biosciences. This conference was attended by HCC researchers, policy makers, payers, members from pharmaceutical industry and patient advocacy groups in and outside of Texas. This report summarizes the results of the conference. The goal of this meeting was to identify different strategies for preventing HCC and evaluate their readiness for implementation. We call for a statewide (1) viral hepatitis elimination program; (2) program to increase NASH and Obesity Awareness; (3) research program to develop health care models that integrate alcohol associated liver disease treatment and treatment for alcohol use disorder; and (4) demonstration projects to evaluate the effectiveness of identifying and linking patient with advanced fibrosis and cirrhosis to clinical care.